A Ubiquitin-Proteasome Gene Signature for Predicting Prognosis in Patients With Lung Adenocarcinoma

Yunliang Tang and Yinhong Guo

Department of Rehabilitation Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China; Department of Oncology, Zhuji People’s Hospital of Zhejiang Province, Zhuji, China

Background: Dysregulation of the ubiquitin-proteasome system (UPS) can lead to instability in the cell cycle and may act as a crucial factor in both tumorigenesis and tumor progression. However, there is no established prognostic signature based on UPS genes (UPSGs) for lung adenocarcinoma (LUAD) despite their value in other cancers.

Methods: We retrospectively evaluated a total of 703 LUAD patients through multivariate Cox and Lasso regression analyses from two datasets, the Cancer Genome Atlas (n = 477) and GSE31210 (n = 226). An independent dataset (GSE50081) containing 128 LUAD samples were used for validation.

Results: An eight-UPSG signature, including ARIH2, FBXO9, KRT8, MYLIP, PSMD2, RNF180, TRIM28, and UBE2V2, was established. Kaplan-Meier survival analysis and time-receiver operating characteristic curves for the training and validation datasets revealed that this risk signature presented with good performance in predicting overall and relapsed-free survival. Based on the signature and its associated clinical features, a nomogram and corresponding web-based calculator for predicting survival were established. Calibration plot and decision curve analyses showed that this model was clinically useful for both the training and validation datasets. Finally, a web-based calculator (https://ostool.shinyapps.io/lungcancer) was built to facilitate convenient clinical application of the signature.

Conclusion: An UPSG based model was developed and validated in this study, which may be useful as a novel prognostic predictor for LUAD.

Keywords: lung adenocarcinoma, ubiquitin-proteasome, prognosis, predictive modeling, gene signature

Abbreviations: LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; OS, overall survival; RFS, relapsed-free survival; UPS, ubiquitin-proteasome system; UPSG, ubiquitin-proteasome system related gene; AUC, area under the curve; ROC, receiver operating characteristic; DCA, decision curve analysis.
INTRODUCTION

Non-small cell lung cancer (NSCLC) constitutes approximately 40%–50% of total lung cancers, which are the leading cause of tumor-associated mortality worldwide (Wu et al., 2019; Siegel et al., 2020). NSCLC is still difficult to diagnose in the early stages due to its insidious progression, and more than two thirds of patients are only diagnosed in its advanced stages. Despite the existence of various chemo/physical/immunological therapies, the 5-year survival rate for patients with any type of lung cancer remains very low (Bade and Dela Cruz, 2020). Histologically, lung adenocarcinoma (LUAD) is the most common form of NSCLC, and comprises nearly 40% of all cases (Hua et al., 2020). Therefore, it is necessary to explore the specific molecular pathogenesis of LUAD and develop novel therapeutic targets for its treatment (Wang J. et al., 2020; Tang et al., 2020).

The ubiquitin-proteasome system (UPS) is a major intracellular protein degradation pathway in eukaryotic organisms, which controls a wide range of physiological processes and disease conditions, such as transcription, translation, DNA repair, and the cell cycle (Chen and Chen, 2016). The UPS primarily comprises the E1, E2, and E3 ubiquitin ligases, the proteasome, and various deubiquitinating enzymes. Dysregulation of the UPS can contribute to the inhibition of cell cycle regulation and disorder of cancer cell metabolism, ultimately leading to carcinogenesis (Dang et al., 2021). In fact, the UPS is already an important target in various cancer treatments, including the use of proteasome and ubiquitin E3 ligases as therapeutic targets for various chemotherapies (Manasanch and Orlowski, 2017). Abnormal expression of different UPS gene families alters proteolysis, inhibiting the proliferation and metastasis of LUAD (He et al., 2021). Thus, evaluating the relationship between UPS and tumorigenesis might provide novel insights into LUAD pathology and facilitate better patient prognosis. However, the prognostic values of UPS-related genes (UPSGs) and their molecular function in LUAD remain poorly understood.

Here, we investigated changes in UPSGs expression in the data downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and then built a scoring model by classifying LUAD patients based on a multi-UPSGs signature, in combination with other clinicopathological factors, to improve our ability to predict the prognosis of LUAD patients, thereby helping to guide clinical treatment. This model might be meaningful for the development of comprehensive therapeutic approaches for LUAD patients.

METHODS

Data Collection

The transcriptomic (HTSeq-FPKM), demographic, and clinical information of patients with LUAD was collected from TCGA (training set) and GEO databases (validation set) for evaluations. First, TCGA-LUAD dataset was curated to remove any cases with incomplete survival data or a follow-up time of less than <30 days, leaving a total of 477 patients with LUAD who were then included in this study. GSE31210 comprised a total of 226 primary LUAD patients at stage I–II, with a median age of 61 years and an age range of 30–76 years; the cohort included 105 male and 121 female patients. GSE50081 comprised a total of 128 LUAD cases with a median age of 70.38 years and an age range of 40.16–85.91 years; this cohort consisted of 98 male and 83 female patients. The clinical characteristics of all three datasets analyzed in this study are summarized in Table 1.

The mutation profiles for each of the UPSGs identified in LUAD patients were downloaded from the cBioPortal database (https://www.cbioportal.org/) (Gao et al., 2013). A total of 804 UPSGs were identified in a previous study and used as the basis of our evaluations in this study (Supplementary Table S1) (Wang et al., 2021).

Establishing a Prognostic UPSG Signature

To narrow the number of candidate UPSGs, we conducted univariate Cox regression analysis on TCGA-LUAD and

| TABLE 1 | Clinical information analyzed in this study. |
|---------|-----------------|-----------------|-----------------|
| Features | TCGA-LUAD | GSE31210 | GSE50081 |
| Sample | 477 | 226 | 128 |
| Mean age (years; range) | 66 (33–88) | 61 (30–76) | 70.38 (40.16–85.91) |
| Gender | | | |
| Male | 215 | 105 | 65 |
| Female | 254 | 121 | 63 |
| Stage | | | |
| I | 253 | 168 | 92 |
| II | 113 | 58 | 36 |
| III | 78 | - | - |
| IV | 25 | - | - |
| Status | | | |
| Alive | 314 | 191 | 76 |
| Dead | 115 | 35 | 52 |
| Platform | Illumina HiSeqV2 | HG-U133_Plus_2 | HG-U133_Plus_2 |

Frontiers in Genetics | www.frontiersin.org May 2022 | Volume 13 | Article 893511
GSE31210 datasets. The overlapping overall survival (OS)-related genes were selected for further study. These targets were then cross-validated using least absolute shrinkage and selection operator (LASSO) regression, which then produced a list of potential predictors with nonzero coefficients using the R packages “glmnet” and “survival.” Finally, we performed multivariate Cox regression analysis on TCGA-LUAD dataset to confirm the identity of highly correlated genes and construct the OS gene signature using the following risk score model:

\[
\text{Risk score} = \sum_{i=0}^{N} (\beta_i \times \text{Exp}_i)
\]

where \(N\) represents the number of UPSGs included in the signature, \(\text{Exp}_i\) represents the mRNA level of these genes, and \(\beta_i\) represents the regression coefficient obtained using the Cox regression analyses.

The patients in each dataset were classified as high- or low-risk, using the median risk score as the cutoff value, and the receiver operating characteristic (ROC) curves were created using the “survivalROC” package in R. The AUC values were calculated to assess the predictive potential of the UPSG signature.

**Validation of the Prognostic Signature**

The prognostic UPSG model was then applied to the GSE50081 validation dataset. Validation dataset was split into high- and low-risk groups for evaluation using Kaplan-Meier curve analysis, time-dependent ROC analysis, and patient outcome distribution to assess the categorization of the UPSG signature.

**Subgroup Analyses of the UPSG Signature**

The clinical usefulness of the prognostic UPSG signature was evaluated through stratification analysis that was performed to investigate the differences in the prognosis of LUAD patients presenting with different clinical characteristics. Based on both characteristics and risk score, the LUAD cases were divided into low- and high-risk groups, and Cox regression was applied to analyze these subgroups.
Estimation of Immune Cell Infiltration
To determine whether and how UPSGs affected the tumor immune microenvironment, Cell type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was used to predict the fractions of immune cell types between the high- and low-risk cohorts. Eventually, 22 types of differentially expressed immune cells associated with specific clinicopathologic characteristics in the high- and low-risk cohorts were identified and depicted as a landscape map.

Construction and Evaluation of the Nomogram
The UPSG signature and clinicopathological predictors were combined to construct a nomogram for TCGA training set. A calibration curve was prepared to assess the agreement between the nomogram model and actual observation. The time-ROC curves and calibration plots were generated, and decision curve analyses (DCA) was used to assess the predictive accuracy of the signature.

RESULTS
Establishing a UPSG Signature
We first defined OS-related UPSGs through a univariate Cox regression analysis from TCGA-LUAD and GSE31210 datasets. The two datasets comprised 95 and 157 OS-related UPSGs, respectively. Then, we reduced the number of OS-related UPSGs by taking the intersection of TCGA-LUAD and GSE31210 datasets. Eventually, 33 overlapping OS-related
TABLE 3 | Stratified survival analyses and clinical characteristics with UPSGs prognostic signature in the TCGA-LUAD cohort (n = 477).

| Characteristics | No. | % | Overall survival |
|-----------------|-----|---|-----------------|
| Age (years)     |     |   |                 |
| <65             | 109 | 44.4 | 2.058 (1.235–3.429) | 0.006 |
| ≥65             | 129 | 55.6 | 2.241 (1.448–3.469) | 0.000 |
| Sex             |     |   |                 |
| Male            | 116 | 46.1 | 2.828 (1.711–4.675) | 0.000 |
| Female          | 122 | 53.9 | 1.686 (1.076–2.644) | 0.023 |
| Stage           |     |   |                 |
| I               | 106 | 53.0 | 1.695 (0.973–2.950) | 0.082 |
| II              | 68  | 23.7 | 1.594 (0.847–2.998) | 0.148 |
| III             | 46  | 16.4 | 2.385 (1.218–4.673) | 0.011 |
| IV              | 16  | 5.2  | 2.683 (0.744–9.673) | 0.132 |
| Unknown         | 2   | 1.7  | --              | --   |
| T stage         |     |   |                 |
| T1              | 65  | 33.3 | 1.578 (0.826–3.016) | 0.167 |
| T2              | 137 | 53.2 | 2.085 (1.345–3.230) | 0.001 |
| T3              | 27  | 9.0  | 5.339 (1.257–24.408) | 0.024 |
| T4              | 8   | 3.8  | 2.823 (0.890–11.549) | 0.149 |
| Unknown         | 1   | 0.6  | --              | --   |
| M stage         |     |   |                 |
| M0              | 156 | 65.6 | 2.181 (1.447–3.286) | 0.000 |
| M1              | 16  | 5.0  | 3.726 (0.821–16.902) | 0.088 |
| Unknown         | 66  | 29.4 | --              | --   |
| N stage         |     |   |                 |
| N0              | 133 | 64.4 | 1.984 (1.228–3.205) | 0.005 |
| N1              | 59  | 18.9 | 1.566 (0.816–2.965) | 0.179 |
| N2              | 40  | 14.0 | 2.133 (1.044–4.358) | 0.038 |
| N3              | 1   | 0.4  | --              | --   |
| Unknown         | 5   | 2.3  | --              | --   |

UPSGs were identified (Supplementary Figure S1). Subsequently, the 33 UPSGs were used in a Lasso-Cox proportional hazards regression and ten-fold cross-validation analyses designed to construct the best gene signature; eventually, 13 UPSGs were identified for downstream analysis (Supplementary Figure S1). Furthermore, a multivariate Cox regression was used to evaluate the Lasso results (Supplementary Figure S1). The prognostic risk score according to the expression of the eight UPSGs was determined as follows: Risk score = ARIII2 × (−0.075232) + FBXO9 × (−0.055219) + KRT8 × 0.00059 + MYLIP × (−0.034945) + PSMD2 × 0.006608 + RNF180 × (−0.123541) + TRIM28 × 0.004102 + UBE2V2 × 0.031981

Moreover, mutation analysis of the eight UPSGs included in the prognostic signature revealed that PSMD2, RNF180, UBE2V2, KRT8, and MYLIP were the most frequently mutated genes. Notably, amplification was the most common type of mutation, and UBE2V2, PSMD2, and FBXO9 were frequently amplified in LUAD (Supplementary Figure S1).

Evaluating the Prognostic Significance of the UPSG Signature

Using the risk score calculation formula derived from the multivariate Cox regression, the risk score for each TCGA-LUAD patient was calculated. Based on the median risk score, patients were separated into high- and low-risk cohorts. The distribution of OS status ranked by risk score is presented in Figure 1A, and the risk score distribution for OS prediction in TCGA dataset is shown in Figure 1B. Differences in expression of the eight UPSGs between normal and tumor tissues is shown in Figure 1C. The results show that KRT8, PSMD2, TRIM28, and UBE2V2 are significantly overexpressed in tumor tissues, while the expression level of FBXO9, MYLIP, and RNF180 is significantly reduced in LUAD (p < 0.05).

We then evaluated the differences in the survival rates of the high- and low-risk groups. The results revealed that the high-risk group exhibited a significantly poorer OS rate than the low-risk group (Figure 1D). In addition, we then used time-dependent ROC curves and their AUC values to evaluate the prognostic significance of this stratification. AUC values were estimated to be 0.700, 0.680, and 0.696 for 1-, 3-, and 5-year OS, respectively (Figure 1E). Moreover, subset analyses using stratification via clinicopathologic feature revealed that this UPSG signature exhibited significant predictive value in most subgroups (Table 3).

Moreover, we also evaluated the prognostic significance of the UPSG signature in the GSE31210 dataset. The distribution of the risk scores for the GSE31210 dataset is presented in Figure 2A. The risk score distribution for OS prediction in TCGA dataset is shown in Figure 2B. The risk score distribution for relapsed-free survival (RFS) prediction is shown in Figure 2C. Survival analysis indicated that patients in the high-risk group had worse OS and RFS compared with the low-risk group (Figures 2D,E). Using the time-dependent ROC curves, the AUC values for 1-, 3-, and 5-year OS prediction were estimated to be 0.610,
Validating the Prognostic Value of the UPSG Signature

To validate the prognostic value of the UPSG signature, we verified its prediction performance in the GSE50081 datasets.

The risk score distribution for OS prediction in the GSE50081 dataset is displayed in Figure 3A, and the risk score distribution for RFS prediction is shown in Figure 4B. Survival analysis indicated that the high-risk group exhibited a worse OS and RFS than the low-risk group (Figures 3C,D). Time-dependent ROC curves for OS prediction revealed AUC values for 1-, 3-, and 5-year OS of 0.63, 0.648, and 0.605, respectively (Figure 3E). Time-dependent ROC curves for RFS prediction revealed AUC values for 1-, 3-, and 5-year RFS of 0.755, 0.698, and 0.629, respectively (Figure 3F).

We then used both univariate and multivariate Cox regression analyses to determine whether this signature and other clinicopathological features were independent predictors of LUAD survival. The results indicated that the UPSG signature may serve as an independent prognostic indicator in both TCGA-LUAD (Figures 4A,B), GSE31210 (Figures 4C,D) datasets, and GSE50081 (Figures 4E,F) dataset.

Correlation Between UPSGs and Clinicopathological Factors

We analyzed the relevance of the signature genes in relation to various clinicopathological parameters of LUAD using the data from TCGA-LUAD training set. These analyses revealed that TRIM28, UBE2V2, KRT8, MYLIP, FBXO9, ARIH2, and RNF180 were all significantly correlated with specific clinicopathological features (Figures 5A–P).

Evaluating the Infiltrating Immune Cell Ratios in High- and Low-Risk LUAD Patients

TCGA-LUAD gene expression data were uploaded to the CIBERSORT platform to evaluate any changes in the overall proportions of the 22 immune cell types in response to their allocation into high- and low-risk groups. Compared to low-risk patients, high-risk patients exhibited an increased proportion of activated CD4 memory T cells, resting NK cells, M0 macrophages, M1 macrophages, and activated mast cells and a reduced proportion of naïve B cells, plasma cells, resting CD4

0.686, and 0.729, respectively (Figure 2F), while those for RFS prediction were 0.677, 0.709, and 0.729, respectively (Figure 2G).
memory T cells, activated NK cells, resting dendritic cells, and resting mast cells (Figure 6).

Establishing and Evaluating a Novel LUAD Nomogram

Given these results, we established a novel nomogram for accurate clinical prediction of LUAD outcomes, using age, gender, stage, and signature risk score in TCGA-LUAD (Figure 7A), and then evaluated its precision using a calibration plot to predict the 1-, 3-, and 5-year OS rates for these samples, all of which exhibited strong correlation with the nomogram findings (Figure 7B). The AUC values for the nomogram at 1-, 3-, and 5-year OS rates were 0.776, 0.758, and 0.762, respectively (Figure 7C). Furthermore, results of DCA for predicting 1-, 3-, and 5-year OS and RFS probability confirmed these results. As shown in Figures 7D-F, the nomogram presented higher net benefit than stage in predicting OS.

Then, we evaluated this nomogram in the GSE31210 dataset. The AUC values of the nomogram at 1-, 3-, and 5-year OS in the ROC curves were 0.851, 0.792, and 0.735, respectively (Figure 8A). The AUC values of the nomogram at 1-, 3-, and 5-year RFS in the ROC curves were 0.769, 0.761, and 0.764, respectively (Figure 8B). Furthermore, DCA for predicting 1-, 3-, and 5-year OS and RFS probability confirmed these results. As shown in Figures 8C,D, the nomogram based on the best model exhibited higher net benefit than stage during OS and RFS prediction.

Finally, we established a web-based tool (https://ostool.shinyapps.io/lungcancer/) for estimating the OS of patients with LUAD (Figures 9A,B) for clinical application of our nomogram and gene signature.
For convenient clinical use and visualization of the prognostic model, we developed a simple-to-operate web-based model (https://ostool.shinyapps.io/lungcancer/) to predict the prognosis of LUAD based on the established nomogram (Figures 9A,B). Estimated LUAD survival probabilities can be obtained by drawing a perpendicular line from the total point axis to the outcome axis.

**DISCUSSION**

Our understanding of the ubiquitin-proteasome system has opened up a new era of anticancer treatment through the maintenance and protection of protein quality control and homeostasis (Li X. et al., 2018; Narayanan et al., 2020). Various UPS inhibitors are being evaluated in clinical trials as novel cancer therapeutics (Johnson, 2015). However, the prognostic value of UPSGs in LUAD patients remains poorly understood. Therefore, complete comprehensive analysis of UPSGs is urgently required to explore their clinical significance in LUAD.

Here, we used RNA-seq data from both TCGA and GEO databases to establish a UPSG prognostic risk signature incorporating ARIH2, FBXO9, KRT8, MYLIP, PSMD2, RNF180, TRIM28, and UBE2V2 for LUAD patients. Kaplan-
Meier survival and ROC curve analyses based on both the training and validation sets indicated that this risk signature exhibited excellent fitting and predictive capacity. Thus, these results could help in the development of novel prognostic biomarkers and provide clinical research ideas for LUAD.

Among the eight UPSGs included in the signature, several genes have previously been explored in terms of their association with LUAD. ARIH2 (Ariadne RBR E3 ubiquitin ligase 2), an E3 ligase whose expression levels are regulated by PABPN1, is one of the most important factors involved in regulating biological function (Raz et al., 2014). A previous study has reported that loss of ARIH2 significantly accelerates the development of resistant HCC827 cells, but the specific mechanism of action needs further investigation (Zeng et al., 2019). FBXO9 (F-box only protein), an SCF (Skp1-Cul-F-box)-type ubiquitin ligase for Neurog2 (Liu J. A. et al., 2020), has been studied in various malignancies. Liu et al. reported that inhibition of FBXO9 increased proteasome activity and sensitivity to bortezomib, suggesting that FBXO9 has an important role in bortezomib susceptibility (Hynes-Smith et al., 2019). However, FBXO9 does not have E3 ligase activity by itself and it is a substrate recognition subunit of an E3 ligase complex. KRT8 (keratin 8), a type II basic intermediate filament protein, is essential for the development and metastasis of various cancers, including LUAD (Xie et al., 2019). Wang et al. explored the expression of KRT8 in LUAD and found that it was overexpressed in tumor tissues and associated with poorer prognosis (Wang W. et al., 2020); these results are consistent with those of our study. MYLIP (myosin regulatory light chain interacting protein), an E3 ubiquitin ligase, which is associated with the regulation of cell motility and migration (Chen et al., 2017), has been found to play a critical role in malignant tumors (Zhao et al., 2020). Ni et al. reported that MYLIP regulates the growth and metastasis-related phenotypes of cervical cancer cells Ni et al. (2021), while the knockdown of PSMD2 (proteasome 26S subunits, non-ATPase 2) has been reported to suppress tumor cell proliferation (Matsuyama et al., 2011; Li Y. et al., 2018; Okumura et al., 2018). PSMD2 has also been shown to be associated with the acquisition of metastatic phenotypes and poor prognosis in various lung cancers (Matsuyama et al., 2011). RNF180 (ring finger protein 180), an important member of the E3 ubiquitin ligase family, acts as a tumor suppressor by inhibiting the proliferation, invasion, and migration of gastric cancer cells (Wu et al., 2020). Previous studies have also indicated that reduced RNF180 expression levels were associated with poor biological behavior in A549 and HCC827 cells (Liu H. et al., 2020). TRIM28 (tripartite motif-containing protein 28) is involved in several cellular processes including gene transcription, cell growth and differentiation, genome stability, immunity, development, and carcinogenesis (Hatakeyama, 2011; Iyengar and Farnham, 2011; Messerschmidt et al., 2012; Sio et al., 2012). Chen et al. reported that TRIM28 is a tumor suppressor in the early transformation process of lung cancer but acts as an oncogene in advanced stages of this disease (Chen et al., 2014). UBE2V2 (ubiquitin-conjugating enzyme E2 variant 2) has sequence similarity to other ubiquitin-conjugating enzymes but lacks the conserved cysteine residues that are essential for the catalytic activity of E2 (Dikshit et al., 2018; Zhao et al., 2018). Hua et al.
reported that UBE2V2 was identified as an independent prognostic indicator for LUAD and might function as a therapeutic target (Hua et al., 2021). The UPS is also regarded as an important player in the regulation of immune cell function and immune response (Çetin et al., 2021). Here, we evaluated the differences in the proportions of 22 immune cell types between low- and high-risk LUAD groups. Our results showed that compared to low-risk patients, high-risk patients have a higher proportion of activated CD4 memory T cells, resting NK cells, M0 macrophages, M1 macrophages, and activated mast cells and a reduced proportion of naïve B cells, plasma cells, resting CD4 memory T cells, activated NK cells, resting dendritic cells, and resting mast cells. These data indicate that this novel gene signature represents differences in immune infiltration, suggesting that immune status may have a critical effect on prognosis.

Given these promising results, we constructed a more reliable and individualized clinical prediction model, using our eight-UPSG signature and several other clinical features to establish a nomogram. The AUC values of the nomogram for TCGA-LUAD data at 1-, 3-, and 5-year OS were 0.776, 0.758, and 0.762, respectively, while those for the GSE31210 dataset were 0.851, 0.792, and 0.735, respectively (Figure 8A). In addition, the AUC values of the nomogram at 1-, 3-, and 5-year RFS in this dataset were 0.769, 0.761, and 0.764, respectively (Figure 8B). DCA results also suggested that the nomogram based on the best model exhibited a larger net prognostic benefit than stage. For the convenience of clinical application, we established a web-based tool for estimating the OS of patients with LUAD. Taken together, these results may enable us to deliver higher accuracy in prognosis prediction for patients with LUAD.

To the best of our knowledge, this is the first study to establish a UPSG signature for predicting the survival of patients with LUAD. However, this study had some limitations. First, we did not investigate the detailed mechanisms of each of the eight UPSGs identified in this study; these underlying mechanisms warrant further investigation through both in vitro and in vivo studies. Second, the inclusion of clinical indicators in the model seems to be insufficient; other factors such as, radiotherapy, surgery type, and targeted drug use might affect the prognosis...
of LUAD. Third, only two GEO datasets were applied for validation; however, further validation using larger datasets is required.

Compared to a signature developed on a complete set of genes, our UPSG signature has a major advantage. We made a comprehensive exploration of the prognostic role of UPSGs in LUAD from a bioinformatic perspective. Compared to the large and complex genome signature, our risk had a better clinical operability which was calculated by several simple UPSGs. However, our research also has a major disadvantage. As our research was based on UPSGs, other prognosis genes were ignored and not included in this study.

In summary, we established a novel signature model for LUAD prognosis based on an eight-UPSG signature, which accurately predicted prognosis of LUAD patients. This signature may serve as an effective tool for designing personalized therapies and guiding medical decisions for LUAD patients in the future. Moreover, these UPSGs in the signature are promising targets for pharmacological and gene therapy in the future.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
AUTHOR CONTRIBUTIONS

YT and YG designed the experiment. YG analyzed the data. YG and YT interpreted the data. YG and YT wrote the manuscript. YG carefully reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Youth Talent Cultivation Project of First Affiliated Hospital of Nanchang University (no. YFYPY202116), and the Science and technology Project of Jiangxi Provincial Health Commission (no.202210362).

REFERENCES

Bade, B. C., and Dela Cruz, C. S. (2020). Lung Cancer 2020. Clin. Chest Med. 41, 1–24. doi:10.1016/j.ccm.2019.10.001

Çetin, G., Klaback, S., Studencka-Turski, M., Krüger, E., and Ebstein, F. (2021). The Ubiquitin-Proteasome System in Immune Cells. Biomolecules 11, 60. doi:10.3390/biom11010060

Chen, H.-Y., and Chen, R.-H. (2016). Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications. Front. Oncol. 6, 113. doi:10.3389/fonc.2016.00113

Chen, L., Muñoz-Antonia, T., and Cress, W. D. (2014). Trim28 Contributes to EMT via Regulation of E-Cadherin and N-Cadherin in Lung Cancer Cell Lines. PLoS One 9, e101040. doi:10.1371/journal.pone.0101040

Chen, S.-F., Chen, P.-Y., Hsu, H.-J., Wu, M.-J., and Yen, J.-H. (2017). Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells. J. Agric. Food Chem. 65, 7908–7918. doi:10.1021/acs.jafc.7b02282

Dang, F., Nie, L., and Wei, W. (2021). Ubiquitin Signaling in Cell Cycle Control and Tumorogenesis. Cell Death Differ. 28, 427–438. doi:10.1038/s41418-020-00648-0

Der, S. D., Sykes, J., Pintilie, M., Zhu, C.-Q., Strumpf, D., Liu, N., et al. (2014). Validation of a Histology-independent Prognostic Gene Signature for Early-Stage, Non-small-cell Lung Cancer Including Stage IA Patients. J. Thorac. Oncol. 9, 59–64. doi:10.1097/jto.0000000000000042

Dikshit, A., Jin, Y. J., Degan, S., Hwang, J., Foster, M. W., Li, C.-Y., et al. (2018). UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. Cancer Res. 78, 6462–6472. doi:10.1158/0008-5472.can-18-1040

ACKNOWLEDGMENTS

We would like to acknowledge TCGA and GEO databases for providing their platforms and those contributors for uploading their valuable datasets.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.893511/full#supplementary-material
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al. (2013). Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signal. 6, p11. doi:10.1126/scisignal.2004988

Hatakeyama, S. (2011). TRIM Proteins and Cancer. Nat. Rev. Cancer 11, 792–804. doi:10.1038/nrc3139

He, D. H., Chen, Y. F., Zhou, Y. L., Zhang, S. B., Hong, M., Yu, X., et al. (2021). The Ubiquitin-Proteasome System: Opportunities for Therapeutic Intervention in Solid Tumors. Endocr. Relat. Cancer 22, T1–T17. doi:10.1530/erc-14-0005

Hynes-Smith, R. W., Swenson, S. A., Vahle, H., Wittorf, K. J., Caplan, M., Amador, C., et al. (2019). Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. Cancers (Basel) 11, 1717. doi:10.3390/cancers11111717

Iyengar, S., and Farnham, P. J. (2011). KAP1 Protein: An Enigmatic Master Regulator of the Genome. J. Biol. Chem. 286, 26267–26276. doi:10.1074/jbc.r111.252569

Johnson, D. E. (2015). The Ubiquitin-Proteasome System: Opportunities for Therapeutic Intervention in Solid Tumors. Endocr. Relat. Cancer 22, T1–T17. doi:10.1530/erc-14-0005

Li, X., Elmira, E., Rohondia, S., Wang, J., Liu, J., and Dou, Q. P. (2018). A Patent Review of the Ubiquitin Ligase System: 2015–2018. Expert Opin. Ther. Pat. 28, 819–937. doi:10.1080/13543776.2018.1549229

Li, Y., Huang, J., Zeng, B., Yang, D., Sun, J., Yin, X., et al. (2018). PSMD2 Regulates Breast Cancer Cell Proliferation and Cell Cycle Progression by Modulating P21 and P27 Proteasomal Degradation. Cancer Lett. 430, 109–122. doi:10.1016/j.canlet.2018.05.018

Liu, H., Yang, P., Li, X., and Jia, Y. (2020). Ring Finger Protein 180 Is Associated with Biological Behavior and Prognosis in Patients with Non-small Cell Lung Cancer. Oncol. Lett. 20, 35. doi:10.3892/ol.2020.11898

Liu, J. A., Tai, A., Hong, J., Cheung, M. P. L., Sham, M. H., Cheah, K. S. E., et al. (2020). Fbxo9 Functions Downstream of Sox10 to Define Neuron-Glial Fate Choice in the Dorsal Root Ganglia through Neuro2 Destabilization. Proc. Natl. Acad. Sci. U.S.A. 117, 4199–4210. doi:10.1073/pnas.1916164117

Mansan, E. E., and Orłowski, R. Z. (2017). Proteasome Inhibitors in Cancer Therapy. Nat. Rev. Clin. Oncol. 14, 417–433. doi:10.1038/nrclinonc.2016.206

Matsuyama, Y., Suzuki, M., Arima, C., Huang, Q. M., Tomida, S., Takeuchi, T., et al. (2011). Proteasomal Non-catalytic Subunit PSMD2 as a Potential Therapeutic Target in Association with Various Clinicopathologic Features in Lung Adenocarcinomas. Mol. Carcinog. 50, 301–309. doi:10.1002/mc.20632

Messes, M., D., de Vries, W., Ito, M., Solter, D., Ferguson-Smith, A., and Knowles, B. B. (2012). Tram28 Is Required for Epigenetic Stability during Mouse Oocyte to Embryo Transition. Science 335, 1499–1502. doi:10.1126/science.1200254

Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., et al. (2020). Targeting the Ubiquitin-Proteasome Pathway to Overcome Anti-cancer Drug Resistance. Drug Resist. Updat. 48, 100663. doi:10.1016/j.drup.2019.100663

Ni, M., Yan, Q., Xue, H., Du, Y., Zhao, S., and Zhao, Z. (2021). Identification of MYLIP Gene and miRNA-802 Involved in the Growth and Metastasis of Cervical Cervical Cells. Cancer Biomark. 30, 287–298. doi:10.3233/cbm-201523

Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., et al. (2012). Identification of Genes Upregulated in ALK-Positive and EGFR/KRAS/ALK-negative Lung Adenocarcinomas. Cancer Res. 72, 100–111. doi:10.1158/0008-5472.can-11-1403

Okumura, T., Ikeda, K., Ujihira, T., Okamoto, K., Horie-Inoue, K., Takeda, S., et al. (2018). Proteasome 26S Subunit PSMD1 Regulates Breast Cancer Cell Growth through PS3 Protein Degradation. J. Biochem. 165, 19–29. doi:10.1093/jb/mvx033

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, or the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.